A team of scientists from 91ֿ and Northeast Ohio Medical University (NEOMED) has begun collaboration on the development of a macrophage targeted mesenchymal stem cell therapy for tissue regeneration and wound healing, a fast-growing research area and major medical challenge.
The $120,000 internally funded program, with equal contributions from both 91ֿ and NEOMED, will support a post-doctoral researcher for a period of two years and is part of 91ֿ’s new internal post-doctoral fellow seed program.
The team of principal investigators for this project is Min-Ho Kim, Ph.D., and Christopher Malcuit, Ph.D., professors from 91ֿ’s new bioengineering program in the College of Applied Engineering, Sustainability and Technology (formerly known as the College of Technology) and Fayez F. Safadi, Ph.D., professor of anatomy and neurobiology and Ohio Research Scholar at NEOMED.
“Post-operative wounds or chronic wounds caused by underlying disease or lowered immunity have high morbidity and significant mortality,” said Grant McGimpsey, 91ֿ’s vice president for research. “Finding ways to address these problems based on regenerative medicine approaches is an exciting effort, and I am very excited about our growing research relationship with NEOMED. The Northeast Ohio region is rich in biomedical research and development opportunities, and it is imperative that research institutions like 91ֿ and NEOMED develop strong partnerships in order to bring our combined expertise to bear on important medical challenges. This project is one example of what I expect to be a growing number of inter-institutional relationships in our region. The particular project that Professors Kim, Malcuit and Safadi are pursuing is an excellent example of the kinds of collaborative partnerships we want to create.
“Beyond the specific scientific and medical goals, this program has been created to further the relationship between 91ֿ’s growing biomedical research expertise and our partner medical university,” McGimpsey continued. “It is designed to allow research teams to quickly gather the data needed to submit competitive proposals to the National Institutes of Health and other government medical funding agencies.”
Malcuit expressed his appreciation for this collaboration.
“I am grateful and honored by the combined support from both 91ֿ and NEOMED in fostering this exciting interdisciplinary project to identify therapeutic targets to treat individuals suffering from acute and chronic wounds,” Malcuit said. “I envision the successful outcome of this collaboration to be just the beginning of much larger future research efforts between our two institutions in the area of regenerative medicine."
Safadi shared his excitement.
“It is great opportunity to initiate such collaboration with the talented faculty at 91ֿ,” Safadi said. “I am very excited about this program, and we are on our way to develop a great relationship with 91ֿ.”
For Kim, the partnership between the two institutions creates great opportunity.
“This is a really valuable opportunity in that this research partnership can bring together and maximize the research strengths in stem cell/ tissue engineering at 91ֿ and in biomedical sciences at NEOMED,” Kim said.
Walter E. Horton Jr., Ph.D., vice president for research and dean of the College of Graduate Studies at NEOMED, said this program helps the working relationship between the two institutions for future ongoing research partnerships.
“This is a very important first step in building ongoing research collaboration between 91ֿ and NEOMED,” he said. “Both 91ֿ and NEOMED have strengths in bioscience research, and by working together, we can more rapidly identify breakthroughs that will improve the health and economic vitality of our region.”
For more information about research at 91ֿ, visit www.kent.edu/research.
For more information about NEOMED, visit .
# # #
Media Contacts:
Emily Vincent, evincen2@kent.edu, 330-672-8595
Heather Bing, hbing@neomed.edu, 330-325-6675